Racially-based disparities in ca on the rise, not due to smoking

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 12
Volume 17
Issue 12

A new study found that recent progress in closing the gap in overall cancer mortality between African Americans and whites may be due primarily to smoking related cancers, and that cancer mortality differences related to screening and treatment may still be increasing. The study is the first to analyze racial and ethnic differences between the two broad categories of disease.

A new study found that recent progress in closing the gap in overall cancer mortality between African Americans and whites may be due primarily to smoking related cancers, and that cancer mortality differences related to screening and treatment may still be increasing. The study is the first to analyze racial and ethnic differences between the two broad categories of disease.

Despite decreases in overall cancer death rates across all racial and ethnic groups since the early 1990s, racial disparities in cancer mortality persist, according to the study results. African Americans had the highest risk of all major ethnic groups in the U.S. of being diagnosed with and dying of cancer (Cancer Epidemiol Biomarkers Prev 17:2908-2912, 2008).

Negative messages make minorities skip screening

Emphasizing the negative consequences of a lack of cancer screening can make minority patients avoid it, according to a study from the St. Louis University School of Public Health.

Robert Nicholson, PhD, and colleagues asked 300 African-American adults to read articles about colon cancer.

The researchers found that articles that relied on scare tactics actually discouraged an interest in screening, while articles about positive outcomes made people more open to screening (Cancer Epidemiol Biomarkers Prev 17:2946-2953, 2008).

Recent Videos
Gedatolisib-based triplet regimens may be effective among patients with prior endocrine resistance or rapid progression following frontline therapy.
Patients with cancer are subjected to fewer radiotherapy-induced toxicities because of newer, more advanced technologies.
Hosts Manojkumar Bupathi, MD, MS, and Benjamin Garmezy, MD, discuss presentations at ESMO 2025 that may impact bladder, kidney, and prostate cancer care.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
A novel cancer database may assist patients determine what clinical trials they are eligible to enroll on and identify the next best steps for treatment.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
An easy-to-access database allows one to see a patient’s cancer stage, prior treatment, and survival outcomes in a single place.
Related Content